Steven Leonard Chapman, Chief Executive Officer of Natera (NASDAQ: NTRA), completed the sale of 73,522 shares of the firm’s common stock during January 20 and 21, 2026, generating proceeds totaling about $17.2 million. These stock disposals were executed at prices between $234.7384 and $235 per share.
The disposition of shares was primarily undertaken to fulfill tax obligations arising from the vesting of previously granted restricted stock units (RSUs). On January 20, Mr. Chapman also exercised 3,386 RSUs, which vested and converted into common shares without a purchase price, reflecting standard executive equity compensation practices.
In parallel with this insider transaction, Natera disclosed preliminary results from its fourth quarter of 2025, indicating nearly 40% revenue growth on a year-over-year basis alongside a 17% increase in test volume. These figures notably exceeded analyst projections and reinforced confidence in the company’s financial momentum.
Reflecting this outlook, Canaccord Genuity reaffirmed its Buy rating on Natera shares, maintaining an optimistic price target of $285.00, signaling sustained positive sentiment around the company’s growth potential.
Beyond financial metrics, Natera announced its collaboration with Exelixis on an ongoing Phase 3 clinical trial aimed at colorectal cancer patients. The trial leverages Natera’s Signatera test to detect molecular residual disease (MRD), identifying patients eligible for enrollment based on MRD status.
The company also revealed a cutting-edge multi-modal artificial intelligence model designed to enhance cancer recurrence risk evaluation, combining diverse data modalities to augment the precision of its Signatera MRD diagnostic test.
Additionally, Natera’s Signatera test contributed to a study published in JAMA Oncology, demonstrating that colorectal cancer patients with detectable circulating tumor DNA (ctDNA) experienced improved survival outcomes when treated with celecoxib addition to chemotherapy.
Natera’s ongoing efforts in prenatal diagnostics are evident with the forthcoming presentation of EXPAND clinical trial data on fetal genetic screening at the Society for Maternal-Fetal Medicine meeting, further exemplifying the company’s commitment to advancing genetic testing technologies.
These recent developments collectively underscore Natera’s active role in both oncology diagnostics and prenatal genetic screening innovation, positioning the company at the forefront of molecular testing advancements within the biotech sector.